Patient advocates have long raised the question about the wisdom in using hormone therapy for extended periods of time. The introduction of intermittent scheduling of hormone therapy (ADT) has become more acceptable thanks to the questions raised by the community and the support of some oncologists who have been willing to think out of the [...]
Following failed radiation therapy (RT) the best treatment of recurrent prostate cancer remains controversial due to the lack of long-term data. Researchers reviewed the survival and establish prognostic indicators for men who received salvage cryotherapy for biopsy-proven recurrent prostate cancer. […]
Whether you are struggling with advanced prostate cancer, or a member of your family is, we all know how this journey can be very difficult. As we look forward to this New Year, 2011, we can be sure that there will be many difficult and down periods, but we should also remember there will also [...]
One of our biggest disputes around hormone deprivation (ADT) concerns the question of scheduling. Traditionally, ADT involved staying on the therapy drug forever. However, ADT causes significant side effects that negatively impacts both the quality of life as well as posing potential significant medical problems. Over the last five or so years there has been [...]
Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Walter Reed Army Medical Center evaluated metastasis-free survival (MFS) and overall survival (OS) among men with a biochemical reoccurrence (PSA only) of prostate cancer after having received a radical prostatectomy but did not receive additional therapy until developing metastases […]
A PSA only recurrence (biochemical failure) post a primary treatment for prostate cancer is relatively common, approximately 30% of those treated! A biochemical failure is characterized a return of increasing PSA without any other evidence of cancer on a scan. Failure can happen immediately after primary treatment has been completed or many years after the [...]
There is a brief, but great YouTube video that very simply and clearly explains the current thinking about how and why prostate cancer becomes androgen independent (castrate resistant). View the video by clicking here Joel T Nowak, M.A., M.S.W.
To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]
Researchers at the Department of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts performed an evaluation of the natural history of castration-resistant non-metastatic prostate cancer. For their analysis, the researchers used data from 331 subjects in a placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time [...]
This study estimated and projected the number of years of potential life lost (YPLL) among men who die of prostate cancer(advanced prostate cancer) in the United States from 2004 through 2050 and compare the projections by race/ethnicity and age, accounting for demographic changes and population growth. The researchers applied the life expectancy method to estimate [...]
